Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m&lt;sup&gt;7&lt;/sup&gt;G modification. Here, METTL1 is linked to non-small cell lung carcinoma.